COMBINATION OF CHEMOTHERAPY AND HORMONE-THERAPY IN ADVANCED BREAST-CANCER

被引:0
作者
MERKLE, E [1 ]
BAR, I [1 ]
HENKE, A [1 ]
BUHNER, M [1 ]
WILDT, L [1 ]
MARTUS, P [1 ]
LANG, N [1 ]
机构
[1] UNIV ERLANGEN NURNBERG,INST MED STAT & DOKUMENTAT,W-8520 ERLANGEN,GERMANY
关键词
ADVANCED BREAST CANCER; COMBINED THERAPY; DECAPEPTYL(R); RESPONSE RATE;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In a prospective study at the Department of Obstetrics and Gynaecology, University of Erlangen, patients with advanced breast carcinoma were treated with a combination of chemotherapy and hormone therapy. Patients received one injection of Decapeptyl(R) in a 28 days interval. At day 12 and 13 of the treatment cycle 40 mug of ethinylestradiol were applicated followed by intravenous chemotherapy with 500 mg/m2 fluorouracil, 10 mg/m2 mitoxantrone and 500 mg/m2 cyclophosphamide took place on day 14. 39 patients were integrated in this study. All of these patients were evaluable regarding the side-effects and 36 patients concerning the response rate. In case of response after 6 cycles the interval between the chemotherapy was prolonged to 6 weeks and the Decapeptyl(R) injections remained in a 4 weeks interval. 15 patients received this combined therapy as a first-line therapy, 24 patients as a second-line therapy or third-line therapy. 2 patients had a complete remission, 14 patients had a partial remission. The objective response rate (CR+PR) was therefore 44 %. In 8 patients the response was classified as no change, consequently the total response rate (CR + PR + NC) was 67 %. 12 patients showed a progression (33 %), 2 patients with several previous treatments suffered an early progress. 3 patients did not finish the therapy. The median response duration was 9 months and the median follow up time until now is 13 months; 24 patients died. Therapy related side-effects were tolerable. As the most frequent side-effect bone marrow suppression were observed. Subjective, for the patients most inconvenient side-effects like nausea, vometing, and alopecia seldomly appeared. The combination of chemotherapy and hormone therapy achieved with a good toleration response rates, which are compatible to international standards of chemotherapy. The exspectations to achieve a better remission rate by a combination of chemotherapy and hormone therapy rather than chemotherapy alone were not fulfilled in this studie.
引用
收藏
页码:220 / 223
页数:4
相关论文
共 50 条
  • [41] MITOXANTRONE AND PREDNIMUSTINE IN THE TREATMENT OF ADVANCED BREAST-CANCER - A TOXIC REGIMEN WITH LOW ACTIVITY
    OBRIEN, MER
    ECCLES, DM
    ALLEN, SG
    KNIGHT, G
    RODGER, A
    CHETTY, U
    SMYTH, JF
    LEONARD, RCF
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1991, 28 (05) : 402 - 404
  • [42] Historical perspective on hormonal therapy of advanced breast cancer
    Jordan, C
    CLINICAL THERAPEUTICS, 2002, 24 : A3 - A16
  • [43] Advanced breast cancer: an update and controversies on diagnosis and therapy
    Nicolini, A
    Cupi, A
    BIOMEDICINE & PHARMACOTHERAPY, 2003, 57 (10) : 439 - 446
  • [44] LONIDAMINE IN MODULATION OF RESPONSE TO ADRIAMYCIN IN ADVANCED BREAST-CANCER - PRELIMINARY-RESULTS
    FRASSINETI, GL
    NANNI, O
    MILANDRI, C
    FERRARI, M
    DEMATTEIS, A
    MUSTACCHI, G
    CARIELLO, S
    MASCIA, V
    SANTORO, A
    AMADORI, D
    LOMBARDI, A
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1994, 4 : 741 - 746
  • [45] Chemotherapy for advanced breast cancer: what influences oncologists' decision making?
    Grunfeld, EA
    Ramirez, AJ
    Maher, EJ
    Peach, D
    Young, T
    Albery, IP
    Richard, MA
    BRITISH JOURNAL OF CANCER, 2001, 84 (09) : 1172 - 1178
  • [46] Dose-intensive chemotherapy for locally advanced breast cancer.
    Schrama J.G.
    Rodenhuis S.
    Current Oncology Reports, 1999, 1 (1) : 23 - 30
  • [47] Single-agent carboplatin chemotherapy in patients with advanced breast cancer
    Gunter, HH
    Wander, HE
    Nagel, GA
    Lelle, RJ
    Glaubitz, M
    WedekingSchohl, H
    Luck, HJ
    Kuhnle, H
    ONKOLOGIE, 1995, 18 (06): : 556 - 560
  • [48] The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice
    Claessens, Anouk K. M.
    Ibragimova, Khava I. E.
    Geurts, Sandra M. E.
    Bos, Monique E. M. M.
    Erdkamp, Frans L. G.
    Tjan-Heijnen, Vivianne C. G.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 153
  • [49] WEEKLY EPIRUBICIN VERSUS DOXORUBICIN AS 2ND LINE THERAPY IN ADVANCED BREAST-CANCER - A RANDOMIZED CLINICAL-TRIAL
    GASPARINI, G
    DALFIOR, S
    PANIZZONI, GA
    FAVRETTO, S
    POZZA, F
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1991, 14 (01): : 38 - 44
  • [50] Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer
    Green, M. D.
    Francis, P. A.
    Gebski, V.
    Harvey, V.
    Karapetis, C.
    Chan, A.
    Snyder, R.
    Fong, A.
    Basser, R.
    Forbes, J. F.
    ANNALS OF ONCOLOGY, 2009, 20 (11) : 1813 - 1817